REDWOOD CITY, California, United States and SHENZHEN, China – May 6, 2026
LTZ Therapeutics has announced the successful completion of an oversubscribed $38 million financing round to accelerate development of its Universal Myeloid Cell Engager (U-MCE™) immunotherapy platform, including advancement of its lead clinical asset LTZ-301 targeting oncology and autoimmune diseases. The financing round was led by GL Ventures, with participation from a sovereign wealth fund and existing investors, bringing the company’s total funding since its 2022 launch to approximately $130 million. The new capital will support ongoing clinical development, regulatory activities, and expansion of LTZ’s next-generation myeloid engager immunotherapy portfolio as the company advances multiple first-in-class programs into human studies.
Funding Supports Phase 1 Development of LTZ-301
LTZ Therapeutics stated that proceeds from the financing will primarily support the ongoing Phase 1 clinical trial of LTZ-301, which is currently enrolling patients across multiple leading U.S. clinical sites. LTZ-301 is a novel myeloid engager bispecific antibody designed to redirect monocytes and macrophages toward CD79b-positive B-cells, enhancing phagocytosis and promoting destruction of cancer cells.
The therapy is being evaluated in patients with relapsed or refractory non-Hodgkin lymphoma (r/r NHL), particularly in cases resistant to existing CD19- or CD20-based therapies. According to the company, preclinical studies demonstrated strong anti-tumor activity alongside a favorable safety profile, supporting the advancement of LTZ-301 into clinical development. The financing will also support the planned Investigational New Drug (IND) filing and Phase 1 initiation of LTZ-232, the company’s second immunotherapy candidate.
Myeloid Cell Engager Platform Targets Tumor Microenvironment
Advertisement
LTZ Therapeutics is developing therapies focused on harnessing the biology of myeloid immune cells, particularly macrophages and monocytes, which are among the most abundant immune cell populations within the tumor microenvironment. Unlike conventional T-cell engager therapies, LTZ’s proprietary U-MCE™ platform is designed to activate macrophage-mediated phagocytosis against cancer cells while potentially offering applications beyond oncology, including autoimmune diseases.
The company believes myeloid biology represents a major untapped opportunity in immunotherapy development, especially in cancers where traditional immune checkpoint inhibitors or T-cell therapies demonstrate limited efficacy. By enhancing anti-tumor immunity through innate immune system activation, LTZ aims to develop differentiated therapies capable of overcoming resistance mechanisms seen with existing immuno-oncology approaches
Leadership Expansion Strengthens Strategic Growth
Alongside the financing announcement, LTZ Therapeutics confirmed the appointment of Erin Lavelle as an independent member of the company’s Board of Directors. Lavelle brings more than 25 years of biotechnology and pharmaceutical industry experience, including leadership roles across both private and public companies.
Most recently, she served as Chief Operating Officer and Chief Financial Officer at ProfoundBio, where she played a key role in the company’s $1.8 billion acquisition by Genmab and an oversubscribed $112 million Series B financing round. LTZ management stated that her experience in operational scaling, financing, and strategic transactions will support the company as it advances its clinical-stage immunotherapy pipeline globally.
Growing Investor Interest in Next-Generation Immunotherapy
The successful financing reflects increasing investor interest in next-generation immunotherapy platforms targeting novel immune mechanisms beyond traditional checkpoint inhibitors and CAR-T therapies. As oncology drug development increasingly shifts toward precision immune modulation and tumor microenvironment targeting, macrophage-engaging therapies are emerging as an important area of innovation.
LTZ Therapeutics believes its differentiated myeloid engager platform could provide new treatment options for both hematologic malignancies and broader immune-mediated diseases. With multiple assets advancing toward clinical milestones, the company is positioning itself within the rapidly expanding immuno-oncology sector focused on first-in-class biologic therapies.
Source: LTZ Therapeutics press release
